Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CID-016
- Development stage
- Preclinical
- Lead developer
- Circle Pharma
- Modality
- Small Molecules, Peptides
- Administration
- Oral
01
Overview
CID-016 (also known as CIR7-7321) is an orally bioavailable macrocyclic peptide developed by Circle Pharma. It acts as a first-in-class dual inhibitor of cyclins A and B, specifically targeting the conserved RxL substrate-binding motif on these cyclins to disrupt their interaction with key substrates (such as E2F and MYT1) and prevent downstream phosphorylation by cyclin-dependent kinases (CDKs). In preclinical studies, CID-016 has demonstrated potent antiproliferative and antitumor activity, inducing tumor regression in patient-derived xenograft (PDX) models of triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and ovarian cancer, particularly in tumors with dysregulation of the RB1/E2F pathway.
02
Targets
CCNA2 (Cyclin A2)CCNB1 (Cyclin B1)
Beyond the preview
Go deeper on CID-016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CID-016.